The acetazolamide market has witnessed significant growth in recent years due to growing prevalence of glaucoma and other ophthalmic diseases. Acetazolamide is an effective diuretic and carbonic anhydrase inhibitor used to treat congestive glaucoma by reducing intraocular pressure. It is available in generic forms as well as proprietary drugs like Diamox. The ease of administration through oral tablets or injections and negligible side effects compared to other glaucoma drugs have propelled the demand for acetazolamide.
Key Takeaways
Key players: Key players operating in the acetazolamide market are Merck KgaA, QIAGEN NV, BioMérieux, Illumina Inc., Micronit BV, PerkinElmer Inc., Thermo Fisher Scientific, Fluidigm Corporation, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Abbott Laboratories, Phalanx Biotech Group, and Danaher Corporation (Cepheid), among others.
Key opportunities: Rising geriatric population prone to developing glaucoma, increasing health awareness, and rapid diagnosis are some of the key opportunities for players in the acetazolamide market. Furthermore, development of novel drug delivery methods and combination therapies will further aid market growth.
Global expansion: Leading manufacturers are focusing on expanding their geographical presence in high growth regions such as Asia Pacific and Latin America. Strategic collaborations with regional distribution partners and development of affordable generic formulations are helping key players penetrate developing markets.
Market drivers:
The growing incidence of glaucoma majorly drives the Acetazolamide Market Demand. As per estimates, over 120 million people worldwide are likely to be affected by glaucoma by 2040. Glaucoma prevalence increases significantly among the elderly population. Rapid aging demographics will augment the target patient pool seeking effective glaucoma treatment medications like acetazolamide.
Get more insights on: - Acetazolamide Market
For Enhanced Understanding, Dive into the Report in the Language that Connects with You:-
· French
· German
· Italian
· Russian
· Japanese
· Chinese
· Korean
